http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102013028793-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0aecab39fcc6eb30bd0fbe1ce9100689 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2013-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12e3a9605c2e102e8de4ad2d2b9c5a54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e375c6b641da2c2c3ec1cfb4cb2bc586 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a92c38836e8997ecfe5360a4e27d8d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e92e69601931cec52211c6387a6c4f35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_775887306c688c111c9bc90875eedafd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4a886b19b093c6b78493d956f2cf1eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b26cc6de058bc1da7bb2b4ca51c18e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_274af56487278c328fd50cc7ef35d2fd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e04df01b5beb7dd83ca363b6da7415f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff5f26cc65cdda2154ebb90800c4ede0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9b5bb72cd59b7ffbfab0dadf3025078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9914d66c306c417e2fd3b07d280dcd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91c046b41f4d8838db5552337fe661fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc71b1594fa42e47d95e4bb65dce5ec6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91e8e94fc41b3c2a95e483e21d1963b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_759cefb34afdda69728146d3eb882ff7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2380f5127cbe8f76964b786c513290eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b91d13124cc7a9c651bca66eacb8528 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_163b1901518f75f09650193d806396b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5debd258aa04cdc325bc32cba98ca4cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f82340e90a47b2682f07cf991a930efc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffcb1c6bcbf8f0d7b4e84abfa8fa994f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_838ed7f29b8dd90d202f1d0a106d429c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ce55a9061e28a75e2db8835b51b3882 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b207f019a09815b68997065aaf383ddf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db74ee69b75ca9651c44dce75ca16ac3 |
| publicationDate | 2015-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102013028793-A2 |
| titleOfInvention | (-) - 5 - hydroxy - 6 ", 6" - dimethylchroman - [2 ", 3": 7,8] - flavanone analgesic effect. |
| abstract | (-) - 5-hydroxy-6 ", 6" -dimethylchromano- [2 ", 3": 7,8] -flavanone analgesic effect. The present invention relates to the use of (-) - 5-hydroxy-6 ", 6" -dimethylchromano- [2 ", 3" 7,8] -flavanone, [a] d20 -65.86 (c = 0 , 05, chcl3), as an analgesic agent in the model of zymosan-induced arthritis in the temporomandibular joint (atm) in rats. (-) - 5-hydroxy-6 ", 6" -dimethylchromano- [2 ", 3": 7,8] -flavanone is a substance in the flavonoid class. These substances arouse the commercial interest of the food, dye and especially pharmaceutical industries due to their biological and pharmacological activities such as antioxidant, anticancer, vasodilator, antiinflammatory, larvicide, antifungal, antiviral and cytotoxic. In this invention, from catalytic hydrogenation of 5-hydroxy-6 ", 6" -dimethylchromen- [2 ", 3": 7,8] -flavaflone gave (-) - 5-hydroxy-6 ", 6 "-dimethylchromano- [2", 3 ": 7,8] -flavanone, [a] d 20, -65.86 (c = 0.05, chcl3), using palladium-adsorbed active charcoal (pd /รง). h2 gas was bubbled into the solution which remained under magnetic stirring for 45 hours, the reaction being monitored by thin layer chromatography (mobile phase: hexane / dichloromethane 60%). After this time, the resulting solution was filtered and concentrated at room temperature. a solid material containing the hydrogenation product was obtained. the characterization of (-) - 5-hydroxy-6 ", 6" -dimethylchromano- [2 ", 3": 7,8] -flavanofla, [a] d20 -65.86 (c = 0.05, chcl3) , was performed by spectroscopic methods: infrared spectroscopy, hydrogen nuclear magnetic resonance, carbon nuclear magnetic resonance 13, and mass spectrometry, including two-dimensional hsqc and hmbc techniques. The literature shows its preparation from 5,7-dihydroxy-8- [3 ', 3'-dimethylallyl] -flavanone but without indicating which enantiomer is obtained. (-) - 5-hydroxy-6 ", 6" -dimethylchromano- [2 ", 3": 7,8] -flavanone, [a] d20 -65.86 (c = ~ 0.05, chci3), at doses of 1 and 10mg / kg administered to rats orally 60 minutes before intra-articular injection of zymosan atm reduced zymozan-induced joint hypemociception in rats. thus the substance (-) - 5-hydroxy-6 ", 6" -dimethylchromano- [2 ", 3": 7,8] -flavanone, [a] d20, -65.86 (c = 0.05 , chcl,) presented analgesic activity, not being statistically different (p> 0.05) from indomethacin, similar aspirin drug, used as positive control |
| priorityDate | 2013-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 125.